Pediatrics

The approval is a milestone for rare disease that has lacked treatments capable of crossing the blood-brain barrier and introduces a new class of agent that pharmacists will need to understand.

Swapping 30 minutes of teen sedentary time for vigorous activity or extra sleep cuts insulin resistance by 15%, aiding type 2 diabetes (T2D) prevention.

Sharon Nachman, MD, equips pharmacists with clear, evidence-based talking points to address vaccine hesitancy and help parents navigate the confusion created by the legal battle over childhood immunization schedules.

Review drug disposal options and discuss proper medication storage when dispensing.

Sharon Nachman, MD, division chief for pediatric infectious disease at Stony Brook Children's Hospital, shares her reaction to the court ruling blocking the scaled-back childhood vaccine schedule.

A federal judge halted HHS Secretary Robert F. Kennedy Jr's rollback of childhood vaccines, freezing ACIP's overhaul and immunization votes amid a medical society lawsuit.

Novo Nordisk's Nicky Kelepouris, MD, discusses the REAL8 trial, the expanded pediatric indications for once-weekly somapacitan, and the pharmacist's role in supporting families navigating long-term growth hormone therapy.

FDA approves secukinumab for adolescents 12 years and older with moderate to severe hidradenitis suppurativa, offering the first IL-17A option and new hope for earlier relief.

Rapid RSV testing in pediatrics cuts unnecessary antibiotic use in young children with viral lung infections.

Ongoing measles outbreaks highlight the impacts of reduced vaccination rates and heightened public distrust in health experts.

New AAAAI data spotlight oral remibrutinib for CSU, next-generation peanut allergy therapies, infant microbiome prevention, and GLP‑1 receptor agonists linked to fewer asthma flares.

Navepegritide becomes the first and only once-weekly treatment to increase linear growth in children with achondroplasia.

Lomitapide demonstrated substantial LDL cholesterol reductions in a pivotal trial.

VOYAGE trial data show dupilumab improves pediatric asthma control and lowers exacerbations versus placebo, with higher remission and lung function gains earlier.

Somapacitan-beco becomes the first and only once-weekly growth hormone approved for children with idiopathic short stature, those born small for gestational age, and those with Noonan syndrome, offering an alternative to daily injections.

Data show the peanut allergy sublingual immunotherapy (SLIT) tablet is well-tolerated across ages, offering promising sublingual immunotherapy desensitization with manageable adverse effects.

AAAAI 2026 highlights STMC-103H live biotherapeutic, showing reduced atopic disease risk in at-risk infants—potentially an early microbiome intervention for atopic dermatitis and food allergy.

Careful history, adherence support, and proper medication technique are central to diagnosing and managing chronic cough in children.

Data presented at AAAAI 2026 show tapinarof cream improves sleep for children as young as 2 years with atopic dermatitis, easing nighttime disruption.

Fluid therapy in pediatrics involves a systematic approach distinguishing maintenance, deficit, and replacement fluids to effectively manage hydration and electrolyte balance.

Trusted pharmacist guidance, motivational interviewing, and evidence-based resources help parents make informed pediatric immunization decisions.

Pitolisant is now the first and only FDA-approved nonscheduled treatment for cataplexy in pediatric and adult patients with narcolepsy.

Shifting federal vaccine guidance fuels parent confusion and uneven care, as clinicians lean on scientific consensus.

The Medications Optimizing Maternal Safety (MOMS) program offers vital support to pregnant patients through community pharmacies.

Ongoing variation in vaccine schedule implementation requires pharmacists and clinicians to collaborate closely, reinforce evidence-based care, and monitor vulnerable populations for gaps in immunization coverage.